These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 18855625)

  • 41. Free fatty acid (FFA) and hydroxy carboxylic acid (HCA) receptors.
    Offermanns S
    Annu Rev Pharmacol Toxicol; 2014; 54():407-34. PubMed ID: 24160702
    [TBL] [Abstract][Full Text] [Related]  

  • 42. TGR5 as a therapeutic target for treating obesity.
    Zhong M
    Curr Top Med Chem; 2010; 10(4):386-96. PubMed ID: 20180762
    [TBL] [Abstract][Full Text] [Related]  

  • 43. GPR43: an emerging target for the potential treatment of type 2 diabetes, obesity and insulin resistance.
    Tiwari A
    Curr Opin Investig Drugs; 2010 Apr; 11(4):385-93. PubMed ID: 20336586
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A novel antidiabetic therapy: free fatty acid receptors as potential drug target.
    Sekiguchi H; Kasubuchi M; Hasegawa S; Pelisch N; Kimura I; Ichimura A
    Curr Diabetes Rev; 2015; 11(2):107-15. PubMed ID: 25732031
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Molecular regulators of lipid metabolism in the intestine - Underestimated therapeutic targets for obesity?
    Dávalos-Salas M; Mariadason JM; Watt MJ; Montgomery MK
    Biochem Pharmacol; 2020 Aug; 178():114091. PubMed ID: 32535104
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Apelin receptors: From signaling to antidiabetic strategy.
    Chaves-Almagro C; Castan-Laurell I; Dray C; Knauf C; Valet P; Masri B
    Eur J Pharmacol; 2015 Sep; 763(Pt B):149-59. PubMed ID: 26007641
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Key Questions for Translation of FFA Receptors: From Pharmacology to Medicines.
    Suckow AT; Briscoe CP
    Handb Exp Pharmacol; 2017; 236():101-131. PubMed ID: 27873087
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [GPR119 Receptor Agonists: Characteristics, Physiological Role, Prospects of Use in the Treatment of Diabetes Mellitus Type 2 and Metabolic Syndrome].
    Tyurenkov IN; Kurkin DV; Bakulin DA; Lomkina EM; Volotova EV
    Usp Fiziol Nauk; 2015; 46(4):28-37. PubMed ID: 27183782
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Biological characteristics and agonists of GPR120 (FFAR4) receptor: the present status of research.
    Li A; Li Y; Du L
    Future Med Chem; 2015; 7(11):1457-68. PubMed ID: 26230883
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intestinal bile acid receptors are key regulators of glucose homeostasis.
    Trabelsi MS; Lestavel S; Staels B; Collet X
    Proc Nutr Soc; 2017 Aug; 76(3):192-202. PubMed ID: 27846919
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Newer GLP-1 receptor agonists and obesity-diabetes.
    Brown E; Cuthbertson DJ; Wilding JP
    Peptides; 2018 Feb; 100():61-67. PubMed ID: 29412833
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Single Amino Acid Mutation (R104P) in the E/DRY Motif of GPR40 Impairs Receptor Function.
    Guo S; Zhang J; Zhang S; Li J
    PLoS One; 2015; 10(10):e0141303. PubMed ID: 26505901
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targeting GPR119 for the potential treatment of type 2 diabetes mellitus.
    Mo XL; Yang Z; Tao YX
    Prog Mol Biol Transl Sci; 2014; 121():95-131. PubMed ID: 24373236
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode.
    Jurica EA; Wu X; Williams KN; Hernandez AS; Nirschl DS; Rampulla RA; Mathur A; Zhou M; Cao G; Xie C; Jacob B; Cai H; Wang T; Murphy BJ; Liu H; Xu C; Kunselman LK; Hicks MB; Sun Q; Schnur DM; Sitkoff DF; Dierks EA; Apedo A; Moore DB; Foster KA; Cvijic ME; Panemangalore R; Flynn NA; Maxwell BD; Hong Y; Tian Y; Wilkes JJ; Zinker BA; Whaley JM; Barrish JC; Robl JA; Ewing WR; Ellsworth BA
    J Med Chem; 2017 Feb; 60(4):1417-1431. PubMed ID: 28112924
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Preventive effect of geniposide on metabolic disease status in spontaneously obese type 2 diabetic mice and free fatty acid-treated HepG2 cells.
    Kojima K; Shimada T; Nagareda Y; Watanabe M; Ishizaki J; Sai Y; Miyamoto K; Aburada M
    Biol Pharm Bull; 2011; 34(10):1613-8. PubMed ID: 21963504
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A novel class of antagonists for the FFAs receptor GPR40.
    Hu H; He LY; Gong Z; Li N; Lu YN; Zhai QW; Liu H; Jiang HL; Zhu WL; Wang HY
    Biochem Biophys Res Commun; 2009 Dec; 390(3):557-63. PubMed ID: 19818732
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The role of polyunsaturated fatty acids and GPR40 receptor in brain.
    Khan MZ; He L
    Neuropharmacology; 2017 Feb; 113(Pt B):639-651. PubMed ID: 26005184
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prominent and emerging anti-diabetic molecular targets.
    Almasi F; Mohammadipanah F
    J Drug Target; 2021 Jun; 29(5):491-506. PubMed ID: 33336602
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Identification of a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with favorable physicochemical and in vitro ADME properties.
    Christiansen E; Urban C; Grundmann M; Due-Hansen ME; Hagesaether E; Schmidt J; Pardo L; Ullrich S; Kostenis E; Kassack M; Ulven T
    J Med Chem; 2011 Oct; 54(19):6691-703. PubMed ID: 21854074
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Free fatty acid receptor 1 as a novel therapeutic target for type 2 diabetes mellitus-current status.
    Eleazu C; Charles A; Eleazu K; Achi N
    Chem Biol Interact; 2018 Jun; 289():32-39. PubMed ID: 29704509
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.